← Back to Search

MyProstateScore 2.0 for Prostate Cancer

N/A
Waitlist Available
Research Sponsored by Qure Healthcare, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up [9 months]
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the MPS 2.0 Test, a new tool for early prostate cancer detection. It involves physicians and their patients to collect real-world data. The test identifies markers indicating prostate cancer, aiding in early diagnosis.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~[9 months]
This trial's timeline: 3 weeks for screening, Varies for treatment, and [9 months] for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Baseline levels of variation in the assessment, surveillance, and management of patients at high risk for prostate cancer among all study participants.
Differences between expected quality of care and actual quality of care
Differences in evidence-based decision making
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MyProstateScore 2.0Experimental Treatment1 Intervention
The intervention will receive information regarding the MyProstateScore 2.0 test and will be given the test results in their round of CPV information and for each sample that they submit.
Group II: Control arm - Baseline comparisonActive Control1 Intervention
The Control group treats their simulated patients using standard practice and has no introduction to the new MyProststate 2.0 test.

Find a Location

Who is running the clinical trial?

Qure Healthcare, LLCLead Sponsor
21 Previous Clinical Trials
3,813 Total Patients Enrolled
2 Trials studying Prostate Cancer
451 Patients Enrolled for Prostate Cancer

Media Library

MyProstateScore 2.0 Clinical Trial Eligibility Overview. Trial Name: NCT05910697 — N/A
Prostate Cancer Research Study Groups: Control arm - Baseline comparison, MyProstateScore 2.0
Prostate Cancer Clinical Trial 2023: MyProstateScore 2.0 Highlights & Side Effects. Trial Name: NCT05910697 — N/A
MyProstateScore 2.0 2023 Treatment Timeline for Medical Study. Trial Name: NCT05910697 — N/A
~57 spots leftby Oct 2025